仁度生物(688193) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥44,815,148.38, representing a year-on-year increase of 15.60%[5] - Total revenue for Q1 2024 reached ¥44,815,148.38, an increase of 15.3% compared to ¥38,766,500.34 in Q1 2023[21] - Net profit for Q1 2024 was ¥3,703,907.82, a significant recovery from a net loss of ¥6,392,335.66 in Q1 2023[22] - Operating profit for Q1 2024 was ¥3,373,723.53, compared to an operating loss of ¥8,175,895.71 in the same period last year[21] - The company reported a total comprehensive income of ¥3,772,583.60 for Q1 2024, compared to a total comprehensive loss of ¥6,909,010.22 in Q1 2023[22] - Basic and diluted earnings per share for Q1 2024 were both ¥0.09, recovering from a loss of ¥0.16 per share in Q1 2023[22] Cash Flow and Operating Activities - The net cash flow from operating activities was ¥8,135,229.74, primarily due to reduced payments for material procurement compared to the previous year[9] - Cash flow from operating activities generated a net inflow of ¥8,135,229.74 in Q1 2024, reversing from a net outflow of ¥6,213,384.20 in Q1 2023[25] - The company experienced a net cash outflow of ¥19,657,841.28 in Q1 2024, compared to a net outflow of ¥25,697,122.20 in Q1 2023[26] Research and Development - Research and development expenses totaled ¥10,176,017.01, accounting for 22.71% of operating revenue, an increase of 0.74 percentage points[6] - Research and development expenses increased to ¥10,176,017.01 in Q1 2024, up from ¥8,518,167.13 in Q1 2023, reflecting a growth of 19.5%[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,040,825,061.67, a decrease of 1.32% from the end of the previous year[6] - As of March 31, 2024, the company's total assets amounted to RMB 1,040,825,061.67, a decrease from RMB 1,054,715,696.08 as of December 31, 2023, reflecting a decline of approximately 1.3%[16] - The company's current assets totaled RMB 887,218,897.39, slightly down from RMB 899,141,593.82 at the end of 2023, indicating a decrease of about 1.4%[16] - The company's total liabilities decreased to RMB 84,756,877.05 from RMB 91,974,054.59, reflecting a decline of approximately 7.9%[18] - The equity attributable to shareholders decreased to RMB 956,068,184.62 from RMB 962,741,641.49, a decrease of about 0.7%[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 4,063[10] - The top ten shareholders held a combined 56.92% of the company's shares, with the largest shareholder owning 19.65%[12] Inventory and Receivables - The company's inventory decreased to RMB 27,025,375.34 from RMB 28,595,133.59, indicating a decline of approximately 5.5%[16] - Accounts receivable decreased to RMB 69,604,041.39 from RMB 76,805,672.80, a reduction of about 9.4%[16] - The company reported a decrease in accounts payable to RMB 3,905,214.08 from RMB 4,093,721.67, a reduction of about 4.6%[17] Government Subsidies - The company received government subsidies amounting to ¥1,486,340.57, which are closely related to its normal business operations[7] Other Information - The company's short-term borrowings and other financial liabilities were not reported in the current quarter[18] - The company has not disclosed any significant new product developments or market expansion strategies in the current report[14]